Aktienanalyse zu enVVeno Medical Corp (NVNO)NVNOenVVeno Medical Corp

enVVeno Medical Corporation is a late clinical-stage medical device company. The Company is focused on the advancement of bioprosthetic (tissue-based) solutions to improve the standard of care for the treatment of venous disease. The Company is developing surgical and non-surgical replacement venous valves for patients suffering from severe chronic venous insufficiency (CVI) of the deep venous system of the leg. The Company’s lead product is the VenoValve, which is a surgical replacement venous valve that is being evaluated in a U.S. pivotal study. The VenoValve is implanted into the femoral vein of the patient in an open surgical procedure via a 5-to-6-inch incision in the upper thigh. The Company is also developing a second product called enVVe, which is a non-surgical, transcatheter-based replacement venous valve. Both the VenoValve and enVVe are designed to act as one-way valves, to help assist in propelling blood up the veins of the leg, and back to the heart and lungs. It operates in the Healthcare sector (SURGICAL & MEDICAL INSTRUMENTS & APPARATUS industry).

Given the current price of $6.39 and the RSI of 36.64, which indicates the stock is in oversold territory, this may seem attractive. However, the company has reported a significant loss of $6.29 per share in the latest earnings report and a staggering 72.22% decline over the past year. The primary risk is the ongoing negative net income trend, with losses projected to continue, making it a poor buy at this time.